- Home
- / CymaBay Therapeutics
CymaBay Therapeutics
Revenue
$31.1 M
FY, 2023
CymaBay Therapeutics Summary
Company Summary
- Overview
- CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and rare diseases. Its main drug candidates are Seladelpar and Arhalofenate. CymaBay's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
- Type
- Subsidiary
- Status
- Active
- Founded
- 1991
- HQ
- Newark, CA, US | view all locations
- Website
- http://www.cymabay.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Robert J. Wills, Chairman
Klara Dickinson, Chief Regulatory and Quality Assurance Officer
Janet Dorling, Director
LocationsView all
1 location detected
Newark, CA HQ
United States
7575 Gateway Blvd #110
CymaBay Therapeutics Financials
Summary Financials
- Revenue (FY, 2023)
- $31.1M
- Net income (FY, 2023)
- ($105.4M)
- Cash (FY, 2023)
- $206.5M
- EBIT (FY, 2023)
- ($101.7M)